Current Report Filing (8-k)
October 25 2016 - 5:25PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
October 25, 2016
ABEONA THERAPEUTICS INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
0-9314
|
83-0221517
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
|
3333 Lee Parkway, Suite 600
Dallas, TX 75219
(Address of principal executive offices)
(Zip Code)
(214) 214-665-9495
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General
Instruction A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01. Other Events
On October 25, 2016, Abeona Therapeutics
Inc. issued a press release entitled “Abeona Therapeutics Announces Fast Track Designation from FDA for ABO-102 in Sanfilippo
Syndrome Type A”. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.
Item 9.01
Financial Statements
and Exhibits.
(d) Exhibits.
Exhibit No.
|
Description
|
99.1
|
Press release dated October 25, 2016, entitled “Abeona Therapeutics Announces Fast Track Designation from FDA for ABO-102 in Sanfilippo Syndrome Type A”
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Abeona Therapeutics Inc.
|
|
(Registrant)
|
|
|
|
|
|
By:
|
/s/ Stephen B. Thompson
|
|
|
Stephen B. Thompson
Vice President Finance
Chief Accounting
Officer
|
Dated: October 25, 2016
EXHIBIT INDEX
Exhibit Number
|
|
|
|
99.1
|
|
Press release dated October 25, 2016, entitled “Abeona Therapeutics Announces Fast Track Designation from FDA for ABO-102 in Sanfilippo Syndrome Type A”
|
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Sep 2023 to Sep 2024